Back to top

Impax Laboratories, Inc. (IPXL) in Focus: Stock Moves 20.6% Higher
September 01, 2017

Read MoreHide Full Article

Impax Laboratories, Inc. (IPXL - Free Report) was a big mover last session, as the company saw its shares rise nearly 21% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $15.1 –$19 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after China's Shanghai Fosun Pharmaceutical (Group) Co. Ltd. disclosed a passive 5.19% stake in the firm.

The company has seen a mixed track record when it comes to estimate revisions of three increase and two decrease over the past two months, while the Zacks Consensus Estimate for the current quarterhas remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.   

Impax Laboratories currently has a Zacks Rank #3 (Hold) while its Earnings ESP is  negative.

Impax Laboratories, Inc. Price and Consensus

Another stock worth mentioning in the Medical sectoris Anthem, Inc. (ANTM - Free Report) which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is IPXL going up? Or down? Predict to see what others think: Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Impax Laboratories, Inc. (IPXL) - free report >>

Anthem, Inc. (ANTM) - free report >>


More from Zacks Tale of the Tape

You May Like